TCGA-DK-A3WW-01A-22R-A23N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.79500657
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.640
- MYC_TARGETS_V1+0.630
- ALLOGRAFT_REJECTION+0.590
- INFLAMMATORY_RESPONSE+0.520
- MYC_TARGETS_V2+0.520
- TNFA_SIGNALING_VIA_NFKB+0.510
- G2M_CHECKPOINT+0.470
- E2F_TARGETS+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
Top 10 suppressed
- MYOGENESIS-0.300
- NOTCH_SIGNALING-0.240
- BILE_ACID_METABOLISM-0.220
- ESTROGEN_RESPONSE_EARLY-0.170
- KRAS_SIGNALING_DN-0.170
- SPERMATOGENESIS-0.150
- HEME_METABOLISM-0.010
- PEROXISOME-0.010
- ESTROGEN_RESPONSE_LATE+0.000
- XENOBIOTIC_METABOLISM+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.920 |
| 2 | TCGA-GC-A6I1-01A-12R-A31N-07 | — | — | 0.916 |
| 3 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.912 |
| 4 | SRR6013600 | — | cohortA1 | 0.911 |
| 5 | TCGA-CN-A49B-01A-31R-A24H-07 | — | — | 0.911 |
| 6 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.910 |
| 7 | TCGA-XF-AAN5-01A-11R-A42T-07 | — | — | 0.901 |
| 8 | SRR1313147 | — | E | 0.899 |
| 9 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.899 |
| 10 | SRR934888 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.630 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |